Ionis posts presentation on olezarsen-triglyceride reductions in severe hypertriglyceridemia

Ionis Pharmaceuticals, Inc.

IONS

0.00

Ionis published slides detailing a pre-specified secondary analysis of CORE-TIMI 72A and CORE2-TIMI 72B trials of olezarsen in severe hypertriglyceridemia.
Analysis assessed whether baseline fibrate use changed olezarsen’s placebo-adjusted triglyceride effect at 6 months and 12 months.
Triglyceride reductions appeared larger with background fibrates, with interaction p-values of 0.02 at 6 months and 0.004 at 12 months.
Baseline cohort: 674 fibrate users vs 387 non-users; median triglycerides 863 mg/dL vs 706 mg/dL at randomization.
Slides conclude results support further study of concomitant fibrate use with APOC3 inhibition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on June 14, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.